Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 15/20 | 0.65 |
| ▸ | REN | P00797 | 1/20 | 0.54 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28951200 | 1.00 | PYGL (0.65) | PYGLRENCYP51A1 | |
| SCHEMBL28951693 | 0.89 | PYGL (0.66) | PYGLRENCYP51A1 | |
| SCHEMBL25517757 | 0.89 | PYGL (0.66) | PYGLRENCYP51A1 | |
| SCHEMBL28951561 | 0.87 | TAS1R3 (0.66) | PYGLRENCYP51A1 | |
| SCHEMBL30174604 | 0.87 | TAS1R3 (0.66) | PYGLRENCYP51A1 | |
| SCHEMBL25517407 | 0.87 | TAS1R3 (0.66) | PYGLRENCYP51A1 | |
| SCHEMBL6163437 | 0.83 | PYGL (0.74) | PYGLCYP51A1 | |
| SCHEMBL24020789 | 0.83 | PYGL (0.54) | PYGL | |
| SCHEMBL30008213 | 0.83 | PYGL (0.54) | PYGL | |
| SCHEMBL25288445 | 0.83 | PYGL (0.54) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4132944-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | Cocrystal Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115698035-A | Inhibitors of norovirus and coronavirus replication | 共晶制药公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | PYGL 889/4885REN 7/4885CYP51A1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.